NOW on demand, The Tate Chronicles with host Jim Tate and guest Greg Archambeau, President of Revalesio Corporation who discusses RNS60, a novel treatment for both ALS and acute ischemic stroke. Phase 3 trials are beginning soon based on promising Phase 2 results.